Page last updated: 2024-09-04

moxifloxacin and sparfloxacin

moxifloxacin has been researched along with sparfloxacin in 54 studies

Compound Research Comparison

Studies (moxifloxacin)	Trials (moxifloxacin)	Recent Studies (post-2010) (moxifloxacin)	Studies (sparfloxacin)	Trials (sparfloxacin)	Recent Studies (post-2010) (sparfloxacin)
3,157	552	1,690	694	69	79

Research

Studies (54)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (5.56)	18.2507
2000's	37 (68.52)	29.6817
2010's	13 (24.07)	24.3611
2020's	1 (1.85)	2.80

Authors

Authors	Studies
Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M	1
Keserü, GM	1
Baroni, M; Cecchetti, V; Cianchetta, G; Cruciani, G; Mannhold, R	1
Li, J; Rajamani, R; Reynolds, CH; Tounge, BA	1
Nagashima, R; Nishikawa, T; Tobita, M	1
Appelbaum, PC; Bhawsar, SB; Bozdogan, B; de Souza, NJ; Desai, VN; Deshpande, PK; Gupte, SV; Hooper, DC; Jacobs, MR; Jha, R; Khorakiwala, HF; Patel, MV; Shetty, N; Shukla, MC; Strahilevitz, J; Yeole, RD	1
Arpin, C; Ba, BB; Caignard, DH; Forfar-Bares, I; Grellet, J; Guillon, J; Jarry, C; Moreau, S; Quentin, C; Vidaillac, C	1
Balasubramanian, V; Bharath, S; Gaonkar, S; Jayaram, R; Jayashree, R; Kaur, P; Mahesh, BN; Nandi, V; Shandil, RK; Suresh, BL	1
Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W	1
Cattoir, V; Mazel, D; Nordmann, P; Poirel, L; Soussy, CJ	1
Cattoir, V; Nordmann, P; Poirel, L	1
Arakawa, Y; Kato, H; Kimura, K; Konda, T; Shibata, N; Shibayama, K; Suzuki, S; Wachino, J; Yamane, K	1
Arsène, S; Leclercq, R	1
Morgan-Linnell, SK; Zechiedrich, L	1
Lombardo, F; Obach, RS; Waters, NJ	1
Jia, L; Sun, H	1
Hiramatsu, K; Kikuchi, K; Ohtsuka, M; Ono, Y; Sasaki, T; Shimizu, K; Takahashi, N	1
Bremont, S; Charavay, F; Courvalin, P; Goarant, C; Le Hello, S; O'Connor, O; Page, S; Vernel-Pauillac, F	1
Caron, G; Ermondi, G; Visentin, S	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Azéma, J; Dewelle, J; Guidetti, B; Kiss, R; Korolyov, A; Le Calve, B; Malet-Martino, M; Martino, R; Mijatovic, T; Vaysse, J	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Khanna, A; Pareek, PK; Raj, VS; Rattan, A; Saini, KS; Sharma, P; Singh, H; Sood, R; Tarai, B; Upadhyay, DJ	1
Imai, YN; Oiki, S; Ryu, S	1
Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS	1
Balakrishnan, G; Bhat, J; Chatterji, M; Dinesh, N; Ghorpade, S; Gorai, G; Guptha, S; Humnabadkar, V; Iyer, PS; Jena, LK; Kaur, P; Khadtare, P; Naik, M; Nandishaiah, R; Narayan, A; Naviri, LK; Panda, M; Ramachandran, V; Sharma, S	1
Cheng, XW; Fan, YL; Feng, LS; Wu, JB; Zhang, FZ	1
Ciura, K; Fallarero, A; Fedorowicz, J; Gilbert-Girard, S; Konopacka, A; Lejnowski, D; Morawska, M; Sączewski, J; Savijoki, K; Skok, Ž; Tomašič, T; Waleron, K	1
Blaskovich, MAT; Pham, TDM; Ziora, ZM	1
Betson, M; Bingham, M; Doyle, P; Hallworth, S; Harvey, R; Huxley, A; Kirk, R; Moat, J; Nelson, G; Pesnot, T; Tait, M	1
Hoban, DJ; Karlowsky, JA; Zhanel, GG	1
Heisig, P; Jones, ME; Klootwijk, M; Schmitz, FJ; Verhoef, J; Visser, MR	1
Engler, B; Fluit, AC; Hadding, U; Heinz, HP; Hofmann, B; Jones, ME; Lückefahr, M; Schmitz, FJ; Verhoef, J	1
Beyer, R; Millichap, JJ; Noskin, GA; Pestova, E; Peterson, LR; Stosor, V	1
Amsterdam, D; Hardy, D; Mandell, LA; Rotstein, C	1
Millichap, JJ; Noskin, GA; Pestova, E; Peterson, LR	1
Fraser, S; Mair, D; Patmore, L; Templeton, A	1
Anderson, ME; Mazur, A; Roden, DM; Yang, T	1
Lister, PD; Sanders, CC	1
Everett, D; Gillespie, SH; Morrissey, I	1
Andrews, JM; Boswell, FJ; Wise, R	1
Blandino, G; Caccamo, F; Milazzo, I; Musumeci, R; Nicoletti, G; Speciale, A	1
Ameyama, S; Shinmura, Y; Takahata, M	1
Paramasivan, CN; Rahman, F; Sulochana, S	1
Abd-El-Fattah, Lel-S; El-Guindi, NM; Mikael, HK; Salem, MY	1
Gidoh, M	1
Jagielski, M; Piekarska, K	1
Gierczyński, R; Jagielski, M; Kochman, M; Piekarska, K; Ławrynowicz-Paciorek, M	1
Mullangi, R; Narasu, L; Shankar, BP; Srinivas, N	1
Anwar, Z; Mostafa, H; Radi, AE; Wahdan, T	1
Lu, J; Pang, Y; Wang, Y; Zhang, Z; Zhao, Y	1
Chaiprasert, A; Disratthakit, A; Doi, N; Leechawengwongs, M; Prammananan, T; Thaipisuttikul, I; Tribuddharat, C	1
Ashfaq, M; Faizan Nazar, M; Iqbal, J; Mulla, SI; Mustafa, G; Nawaz Khan, K; Saif Ur Rehman, M; Sun, Q; Yu, CP	1

Reviews

2 review(s) available for moxifloxacin and sparfloxacin

Article	Year
Fluoroquinolone derivatives and their anti-tubercular activities. European journal of medicinal chemistry, 2018, Feb-25, Volume: 146 Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Tuberculosis	2018
Quinolone antibiotics. MedChemComm, 2019, Oct-01, Volume: 10, Issue:10 Topics:	2019

Other Studies

52 other study(ies) available for moxifloxacin and sparfloxacin

Article	Year
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. Journal of medicinal chemistry, 2002, Aug-29, Volume: 45, Issue:18 Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship	2002
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorganic & medicinal chemistry letters, 2003, Aug-18, Volume: 13, Issue:16 Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship	2003
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach. Journal of medicinal chemistry, 2004, Jun-03, Volume: 47, Issue:12 Topics: Anti-Bacterial Agents; Enterococcus faecalis; Escherichia coli; Models, Molecular; Pseudomonas aeruginosa; Quantitative Structure-Activity Relationship; Quinolones; Staphylococcus aureus; Thermodynamics	2004
A two-state homology model of the hERG K+ channel: application to ligand binding. Bioorganic & medicinal chemistry letters, 2005, Mar-15, Volume: 15, Issue:6 Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation	2005
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. Bioorganic & medicinal chemistry letters, 2005, Jun-02, Volume: 15, Issue:11 Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated	2005
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. Journal of medicinal chemistry, 2005, Aug-11, Volume: 48, Issue:16 Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Dogs; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Mutation; Prodrugs; Quinolizines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Vancomycin Resistance	2005
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:3 Topics: Anti-Bacterial Agents; Bacterial Proteins; Culture Media; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Indicators and Reagents; Kinetics; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Norfloxacin; Omeprazole; Staphylococcus aureus; Structure-Activity Relationship	2007
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:2 Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Predictive Value of Tests; Quinolines; Time Factors; Tuberculosis	2007
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:5 Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors	2007
Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7 Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Computer Simulation; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Genes, Bacterial; Microbial Sensitivity Tests; Molecular Sequence Data; Nucleic Acid Amplification Techniques; Open Reading Frames; Plasmids; Polymerase Chain Reaction; Quinolones; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Vibrio	2007
Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7 Topics: Anti-Bacterial Agents; Bacterial Proteins; Child, Preschool; Conjugation, Genetic; Drug Resistance, Bacterial; Enterobacter cloacae; Escherichia coli; France; Genes, Bacterial; Humans; Microbial Sensitivity Tests; Plasmids; Quinolones; Transformation, Genetic	2007
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:9 Topics: Amino Acid Sequence; Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chitosan; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Malates; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Transformation, Bacterial; Uncoupling Agents	2007
Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:9 Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Culture Media; DNA Gyrase; Drug Resistance, Bacterial; Enterococcus faecalis; Fluoroquinolones; Gene Expression Regulation, Bacterial; Genes, Bacterial; Microbial Sensitivity Tests; Molecular Sequence Data; Reverse Transcriptase Polymerase Chain Reaction	2007
Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:11 Topics: DNA Topoisomerases; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Mutation	2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Support vector machines classification of hERG liabilities based on atom types. Bioorganic & medicinal chemistry, 2008, Jun-01, Volume: 16, Issue:11 Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve	2008
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10 Topics: Alleles; Amino Acid Sequence; Anti-Bacterial Agents; Base Sequence; Chromosomes, Bacterial; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Gram-Negative Bacterial Infections; Humans; Molecular Sequence Data; Sequence Homology, Amino Acid; Stenotrophomonas maltophilia	2008
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:11 Topics: Amino Acid Substitution; Base Sequence; DNA Gyrase; DNA Mutational Analysis; DNA Primers; DNA Probes; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Humans; Nucleic Acid Denaturation; Point Mutation; Polymerase Chain Reaction; Streptococcus pneumoniae; Thermodynamics	2008
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers. European journal of medicinal chemistry, 2009, Volume: 44, Issue:5 Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship	2009
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents. Bioorganic & medicinal chemistry, 2009, Aug-01, Volume: 17, Issue:15 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum Tolerated Dose; Mice; Neoplasms; Piperazine; Piperazines	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11 Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; DNA Gyrase; DNA Mutational Analysis; DNA-Directed RNA Polymerases; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; India; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Point Mutation; Polymerase Chain Reaction; Rifampin	2010
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel. Bioorganic & medicinal chemistry letters, 2013, Jul-01, Volume: 23, Issue:13 Topics: Anti-Bacterial Agents; Binding Sites; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Models, Molecular; Potassium Channel Blockers; Structure-Activity Relationship	2013
MICE models: superior to the HERG model in predicting Torsade de Pointes. Scientific reports, 2013, Volume: 3 Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes	2013
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis. ACS medicinal chemistry letters, 2014, Sep-11, Volume: 5, Issue:9 Topics:	2014
Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. European journal of medicinal chemistry, 2019, Oct-01, Volume: 179 Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Positive Bacteria; HEK293 Cells; Humans; Microbial Sensitivity Tests; Molecular Structure; Quaternary Ammonium Compounds; Quinolones; Structure-Activity Relationship	2019
Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. Bioorganic & medicinal chemistry letters, 2020, 10-15, Volume: 30, Issue:20 Topics: Anti-Bacterial Agents; Bacterial Infections; Carbon; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Molecular Structure; Neisseria gonorrhoeae; Structure-Activity Relationship	2020
In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species. Diagnostic microbiology and infectious disease, 1998, Volume: 31, Issue:2 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Drug Resistance, Microbial; Enterococcus; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Vancomycin	1998
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-re Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:2 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus; Vancomycin; Virginiamycin	1999
The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. The Journal of antimicrobial chemotherapy, 1998, Volume: 42, Issue:6 Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Genes, Bacterial; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Polymerase Chain Reaction; Quinolines; Reserpine; Staphylococcal Infections; Staphylococcus aureus	1998
A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:3 Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Microbial; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Quinolines; Reserpine; Staphylococcus aureus; Streptococcus pneumoniae	2000
Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci. Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:3 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Fluoroquinolones; Gemifloxacin; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines	2000
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. The Journal of antimicrobial chemotherapy, 2000, Volume: 45, Issue:5 Topics: Anti-Infective Agents; Aza Compounds; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Pneumococcal Infections; Polymerase Chain Reaction; Quinolines; Reserpine; Sequence Analysis, DNA; Streptococcus pneumoniae	2000
Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration. European journal of pharmacology, 2000, Oct-20, Volume: 406, Issue:3 Topics: Action Potentials; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Dogs; Female; Fluoroquinolones; Heart; Male; Moxifloxacin; Piperazines; Quinolines; Time Factors	2000
Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. The Journal of pharmacology and experimental therapeutics, 2001, Volume: 296, Issue:3 Topics: 4-Quinolones; Animals; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Cation Transport Proteins; DNA-Binding Proteins; Electrocardiography; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Gatifloxacin; Long QT Syndrome; Mice; Models, Animal; Moxifloxacin; Patch-Clamp Techniques; Piperazines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quinolines; Rabbits; Trans-Activators; Tumor Cells, Cultured	2001
Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. The Journal of antimicrobial chemotherapy, 2001, Volume: 47, Issue:6 Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae; Time Factors	2001
A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model. Journal of medical microbiology, 2001, Volume: 50, Issue:6 Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mycobacterium fortuitum; Mycobacterium Infections, Nontuberculous; Ofloxacin; Quinolines	2001
Comparison of the in vitro activities of BMS-284756 and four fluoroquinolones against Streptococcus pneumoniae. The Journal of antimicrobial chemotherapy, 2001, Volume: 48, Issue:3 Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Humans; Indoles; Microbial Sensitivity Tests; Moxifloxacin; Norfloxacin; Quinolines; Quinolones; Streptococcus pneumoniae	2001
Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates. International journal of antimicrobial agents, 2002, Volume: 19, Issue:2 Topics: Aerobiosis; Anaerobiosis; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteria; Ceftriaxone; Cephalosporins; Ciprofloxacin; Clindamycin; Clostridium; Drug Resistance, Multiple, Bacterial; Erythromycin; Fluoroquinolones; Imipenem; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma; Quinolines; Streptococcus; Teicoplanin; Thienamycins; Vancomycin	2002
Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae. Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:7 Topics: Anti-Infective Agents; Aza Compounds; Chlamydophila pneumoniae; DNA Gyrase; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Indoles; Levofloxacin; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Topoisomerase II Inhibitors	2003
In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. Journal of chemotherapy (Florence, Italy), 2005, Volume: 17, Issue:2 Topics: Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Quinolones; Sampling Studies; Sensitivity and Specificity	2005
Stability indicating methods for the determination of some fluoroquinolones in the presence of their decarboxylated degrades. Chemical & pharmaceutical bulletin, 2006, Volume: 54, Issue:12 Topics: Aza Compounds; Chromatography, Thin Layer; Densitometry; Drug Stability; Fluoroquinolones; Molecular Structure; Moxifloxacin; Quinolines; Spectrophotometry	2006
[In-vitro and in-vivo activities of moxifloxacin and garenoxacin against Mycobacterium leprae]. Nihon Hansenbyo Gakkai zasshi = Japanese journal of leprosy : official organ of the Japanese Leprosy Association, 2007, Volume: 76, Issue:1 Topics: Animals; Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Leprostatic Agents; Levofloxacin; Mice; Mice, Inbred BALB C; Mice, Nude; Moxifloxacin; Mycobacterium leprae; Ofloxacin; Quinolines; Rifampin	2007
[Genetical conditioning of fluoroquinolone resistance mechanisms of clinical enterococcus faecalis strains. II. The mutations present in the qrdrs of gyrA, gyrB, parC and parE genes]. Medycyna doswiadczalna i mikrobiologia, 2007, Volume: 59, Issue:4 Topics: Amino Acid Substitution; Aza Compounds; Bacterial Proteins; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Enterococcus faecalis; Fluoroquinolones; Genes, Bacterial; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Polymerase Chain Reaction; Quinolines; Species Specificity	2007
Novel gyrase mutations and characterization of ciprofloxacin-resistant clinical strains of Enterococcus faecalis isolated in Poland. Polish journal of microbiology, 2008, Volume: 57, Issue:2 Topics: Amino Acid Substitution; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Enterococcus faecalis; Fluoroquinolones; Genes, Bacterial; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Poland; Polymerase Chain Reaction; Quinolines; Sequence Analysis, DNA	2008
Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using levofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study. Biomedical chromatography : BMC, 2008, Volume: 22, Issue:11 Topics: Administration, Oral; Analytic Sample Preparation Methods; Aza Compounds; Chromatography, High Pressure Liquid; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Reference Standards; Sensitivity and Specificity	2008
Electrochemical determination of gatifloxacin, moxifloxacin and sparfloxacin fluoroquinolonic antibiotics on glassy carbon electrode in pharmaceutical formulations. Drug testing and analysis, 2010, Volume: 2, Issue:8 Topics: Anti-Infective Agents; Aza Compounds; Carbon; Electrochemistry; Electrodes; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Moxifloxacin; Quinolines; Tablets	2010
Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:1 Topics: Antitubercular Agents; China; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prevalence	2014
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:9 Topics: Aminopyridines; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Gene Expression; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Thailand; Tuberculosis, Pulmonary	2016
Ecological risk assessment of pharmaceuticals in the receiving environment of pharmaceutical wastewater in Pakistan. Ecotoxicology and environmental safety, 2017, Volume: 136 Topics: Animals; Diclofenac; Ecology; Environmental Monitoring; Fishes; Fluoroquinolones; Gemifloxacin; Ibuprofen; Moxifloxacin; Naphthyridines; Pakistan; Risk Assessment; Sewage; Wastewater; Water Pollutants, Chemical	2017